B+
Bull case
25%
Probability
Target price
$7.50
+84.3% vs current
ANTX
AN2 TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.00
-1.7% vs current
B-
Bear case
30%
Probability
Target price
$2.00
-50.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+53.9
Score
AI commentary
Sentiment remains cautious-neutral. Company sources verified in March and April support better runway and a fuller 2026 catalyst calendar, but the deterministic prior is still negative and the follow-up earnings check did not surface a new May 2026 company release or delayed analyst revision as of 2026-05-04, so there is no clear post-print thesis upgrade to underwrite. The stock still looks like a low-coverage milestone-monitoring biotech where financing mechanics and execution timing matter more than near-term fundamental revision [#IR-2026-03-17] [#8-K-2026-04-09] [#IR-2026-05-04].
RankAlpha Sentiment Codex - 2026-05-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystATM capacity offsets runway support with renewed dilution overhangHigh impact
AN2 added an $80 million Jefferies at-the-market facility on April 9, 2026 after its March 2026 $40 million private placement, which supports liquidity but reintroduces supply risk for a micro-cap stock already trading on financing sensitivity [#8-K-2026-04-09] [#IR-2026-03-09] [#IR-2026-03-17].
2026-09-30eventPolycythemia vera Phase 2 start remains the nearest company-controlled clinical milestoneHigh impact
Management said oral epetraborole's Phase 2 proof-of-concept study in polycythemia vera is expected to begin in India in 3Q26, with periodic data readouts possible as early as 4Q26, making this the clearest nearer-term upside proof point if execution stays on schedule [#IR-2026-03-17] [#10-K-2026-03-17].
2027-12-31catalystM. abscessus Phase 2 IIT has begun screening but value realization is pushed to late 2027High impact
AN2 announced initiation of the 84-patient investigator-initiated Phase 2 trial in M. abscessus lung disease, with patient screening underway and topline data planned for late 2027; the study adds meaningful optionality but still leaves a long execution window and limited near-term readthrough [#IR-2026-03-31] [#IR-2026-03-17].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology